DK1210068T3 - Anvendelse af simple aminosyrer til dannelse af poröse partikler - Google Patents

Anvendelse af simple aminosyrer til dannelse af poröse partikler

Info

Publication number
DK1210068T3
DK1210068T3 DK00957716T DK00957716T DK1210068T3 DK 1210068 T3 DK1210068 T3 DK 1210068T3 DK 00957716 T DK00957716 T DK 00957716T DK 00957716 T DK00957716 T DK 00957716T DK 1210068 T3 DK1210068 T3 DK 1210068T3
Authority
DK
Denmark
Prior art keywords
amino acids
porous particles
particles
form porous
simple amino
Prior art date
Application number
DK00957716T
Other languages
English (en)
Inventor
Richard P Batycky
Ralph W Niven
Michael M Lipp
Original Assignee
Advanced Inhalation Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Inhalation Res Inc filed Critical Advanced Inhalation Res Inc
Application granted granted Critical
Publication of DK1210068T3 publication Critical patent/DK1210068T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0082—Lung surfactant, artificial mucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK00957716T 1999-08-25 2000-08-23 Anvendelse af simple aminosyrer til dannelse af poröse partikler DK1210068T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/382,959 US6586008B1 (en) 1999-08-25 1999-08-25 Use of simple amino acids to form porous particles during spray drying

Publications (1)

Publication Number Publication Date
DK1210068T3 true DK1210068T3 (da) 2006-07-17

Family

ID=23511119

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00957716T DK1210068T3 (da) 1999-08-25 2000-08-23 Anvendelse af simple aminosyrer til dannelse af poröse partikler

Country Status (11)

Country Link
US (8) US6586008B1 (da)
EP (2) EP1210068B1 (da)
JP (1) JP2003507412A (da)
AT (1) ATE319429T1 (da)
AU (1) AU764738B2 (da)
CA (1) CA2382651C (da)
DE (1) DE60026544T2 (da)
DK (1) DK1210068T3 (da)
ES (1) ES2258981T3 (da)
PT (1) PT1210068E (da)
WO (1) WO2001013893A2 (da)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020052310A1 (en) * 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US6458338B1 (en) * 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6749835B1 (en) * 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
WO2002032396A2 (en) * 2000-10-16 2002-04-25 Massachusetts Institute Of Technology Lipid-protein-sugar particles for delivery of nucleic acids
PL365736A1 (en) * 2001-02-06 2005-01-10 Innovata Biomed Limited Bimodal dry powder formulation for inhalation
US6848197B2 (en) * 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
WO2003035028A1 (en) * 2001-10-19 2003-05-01 Nektar Therapeutics Modulating charge density to produce improvements in the characteristics of spray-dried proteins
WO2003035051A2 (en) * 2001-10-19 2003-05-01 Inhale Therapeutic Systems, Inc. The use of proton sequestering agents in drug formulations
EP1458362A4 (en) * 2001-11-19 2006-01-18 Becton Dickinson Co PHARMACEUTICAL COMPOSITIONS IN PARTICULAR FORM
CA2465779A1 (en) * 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery
WO2003053411A1 (en) 2001-12-19 2003-07-03 Nektar Therapeutics Pulmonary delivery of aminoglycosides
CA2477592A1 (en) * 2002-03-18 2003-09-25 Yamanouchi Pharmaceutical Co., Ltd. Powdery medicinal compositions for inhalation and process for producing the same
US7754242B2 (en) * 2002-03-20 2010-07-13 Alkermes, Inc. Inhalable sustained therapeutic formulations
US20110123574A1 (en) * 2002-03-20 2011-05-26 Alkermes, Inc. Inhalable sustained therapeutic formulations
AU2003230689B2 (en) 2002-03-20 2006-06-29 Alkermes, Inc. Inhalable sustained therapeutic formulations
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
EP1617820B1 (en) 2003-04-14 2018-03-21 Vectura Limited Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
US7862834B2 (en) * 2003-05-28 2011-01-04 Novartis Pharma Ag Pharmaceutical formulation comprising a water-insoluble active agent
EP1663164A2 (en) * 2003-09-15 2006-06-07 Vectura Limited Methods for preparing pharmaceutical compositions
AU2005212315A1 (en) * 2004-02-10 2005-08-25 Advanced Inhalation Research, Inc. Particles for inhalation rapid release properties
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
HRP20130076T1 (hr) 2004-06-18 2013-03-31 Novartis Ag Formulacije tobramicina za lijeäśenje endobronhijalnih infekcija
JP2008507585A (ja) * 2004-07-26 2008-03-13 コセリックス インク 微粒子製剤を用いて吸入したイロプロストによる肺高血圧症の治療
RU2007119721A (ru) 2004-10-29 2008-12-10 Президент Энд Феллоуз Оф Гарвард Колледж (Us) Частицы для лечения легочной инфекции
US20060105051A1 (en) * 2004-11-18 2006-05-18 Blair Jackson Manufacture of particles for pulmonary drug delivery by carbon dioxide assisted nebulization
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20060134009A1 (en) * 2004-12-16 2006-06-22 Daniel Deaver Low dose corticosteroid powders for inhalation
US8524734B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
CN104173323B (zh) 2005-05-18 2018-04-03 拉普特制药有限公司 气溶胶化的氟喹诺酮类药物及其应用
NZ592293A (en) * 2005-11-28 2012-10-26 Verrow Pharmaceuticals Inc Compositions comprising an oligosaccharide such as a cyclodextrin for reducing the nephrotoxicity of other drugs
GB0524194D0 (en) * 2005-11-28 2006-01-04 Univ Aston Respirable powders
US20070219127A1 (en) * 2006-03-20 2007-09-20 Walt John G Cyclosporin a compositions
DE102006030164A1 (de) * 2006-06-29 2008-01-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Pulver
WO2008130220A1 (en) * 2007-04-20 2008-10-30 N.V. Nutricia Process for dispersing amino acids
KR20110091510A (ko) 2008-10-07 2011-08-11 엠펙스 파마슈티컬즈, 인코포레이티드 약동학 개선을 위한 에어로졸 플루오로퀴놀론 제형
EP2346509B1 (en) 2008-10-07 2020-05-13 Horizon Orphan LLC Inhalation of levofloxacin for reducing lung inflammation
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
EP3111926B1 (en) 2009-05-29 2019-12-11 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents
RU2015130524A (ru) 2009-09-04 2018-12-21 Раптор Фармасьютикалз Инк. Применение левофлоксацина в форме аэрозоля для лечения муковисцидоза
DK2670242T3 (da) 2011-01-31 2022-05-02 Avalyn Pharma Inc Aerosolpirfenidon- og pyridonanalogforbindelser og anvendelser deraf
US9572774B2 (en) 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
CA2836643C (en) * 2011-05-19 2017-11-14 Savara, Inc. Dry powder vancomycin compositions and associated methods
CN102225058A (zh) * 2011-06-22 2011-10-26 中国药科大学 磷酸奥司他韦吸入粉雾剂及其制备方法
BR112015010601B1 (pt) 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
CN105163735B (zh) 2013-02-01 2018-12-11 格力尔罗格克斯股份有限公司 用于治疗神经退行性疾病和其他疾病的组合物和方法
RU2696582C2 (ru) 2013-03-15 2019-08-05 Перл Терапьютикс, Инк. Способы и системы кондиционирования дисперсных кристаллических материалов
CA3172586C (en) 2013-07-31 2025-10-14 Avalyn Pharma Inc. IMATINIB AEROSOL COMPOUNDS AND RELATED USES
EP4491180A1 (en) 2014-01-10 2025-01-15 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US20160367520A1 (en) 2014-02-10 2016-12-22 Patara Pharma, LLC Mast cell stabilizers for lung disease treatment
DK3104853T3 (da) 2014-02-10 2019-12-09 Respivant Sciences Gmbh Behandling med mastcellestabilisatorer til systemiske forstyrrelser
EA035372B1 (ru) * 2014-07-30 2020-06-03 Джиноум Протекшн, Инк. Флагеллиновые композиции и их применение
GB201415381D0 (en) 2014-08-29 2014-10-15 Algipharma As Inhalable powder formulations of alginate oligomers
ES2841933T3 (es) 2014-10-31 2021-07-12 Univ Monash Formulación en polvo
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
WO2017127641A1 (en) * 2016-01-20 2017-07-27 Flurry Powders Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
US11833118B2 (en) 2016-01-20 2023-12-05 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
AU2017281931B2 (en) * 2016-06-24 2023-02-02 Merz Pharmaceuticals, Llc Surfactant formulations for inhalation
EP3478265B1 (en) 2016-06-30 2025-01-01 Philip Morris Products S.A. Nicotine particles
MX385972B (es) * 2016-06-30 2025-03-18 Philip Morris Products Sa Partículas y composiciones de nicotina.
AU2017321495A1 (en) 2016-08-31 2019-03-21 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
EP3522983A4 (en) 2016-10-07 2020-06-03 Respivant Sciences GmbH CROMOLYNE-BASED COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS
TW201818933A (zh) 2016-10-21 2018-06-01 美商吉利亞洛吉克斯公司 用於神經退化性及其他疾病的治療之組成物和方法
CA3048677A1 (en) * 2017-03-07 2018-09-13 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
JP7210476B2 (ja) 2017-05-22 2023-01-23 インスメッド インコーポレイテッド リポ‐グリコペプチド可切断性誘導体及びその使用
CA3085943A1 (en) * 2017-12-21 2019-06-27 Civitas Therapeutics, Inc. Surfactant formulations for inhalation
JP7335263B2 (ja) * 2017-12-21 2023-08-29 キウィタス セラピューティクス，インコーポレイテッド 吸入のための界面活性剤製剤
MX2021000908A (es) 2018-07-23 2021-06-08 Trevi Therapeutics Inc Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.
JP2023510341A (ja) 2020-01-10 2023-03-13 トレビ セラピューティクス インコーポレイテッド ナルブフィン投与メソッド

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
CZ286632B6 (cs) 1992-09-29 2000-05-17 Inhale Therapeutic Systems Farmaceutický prostředek
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
EP1462096B1 (en) 1994-03-07 2008-12-10 Nektar Therapeutics Methods and compositions for pulmonary delivery of insulin
CN1073119C (zh) 1994-05-18 2001-10-17 吸入治疗系统公司 干扰素干粉配方的方法及组合物
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
ES2237767T3 (es) 1995-04-14 2005-08-01 Nektar Therapeutics Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada.
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
WO1998016245A1 (fr) * 1996-10-15 1998-04-23 Shionogi & Co., Ltd. Procede de determination d'un auto-anticorps
ATE287257T1 (de) 1997-01-16 2005-02-15 Massachusetts Inst Technology Zubereitung von partikelhaltigen arzneimitteln zur inhalation
CA2304975C (en) 1997-09-29 2009-06-16 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
GB9827145D0 (en) 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders

Also Published As

Publication number Publication date
US6586008B1 (en) 2003-07-01
EP1637128A2 (en) 2006-03-22
DE60026544T2 (de) 2007-01-11
WO2001013893A3 (en) 2001-05-03
US20080160092A1 (en) 2008-07-03
ES2258981T3 (es) 2006-09-16
WO2001013893A2 (en) 2001-03-01
PT1210068E (pt) 2006-07-31
DE60026544D1 (de) 2006-05-04
EP1210068B1 (en) 2006-03-08
US8268358B2 (en) 2012-09-18
US20130071440A1 (en) 2013-03-21
AU764738B2 (en) 2003-08-28
ATE319429T1 (de) 2006-03-15
EP1637128A3 (en) 2008-03-05
US20080160098A1 (en) 2008-07-03
JP2003507412A (ja) 2003-02-25
US20160287517A1 (en) 2016-10-06
US20070104658A1 (en) 2007-05-10
US20170354602A1 (en) 2017-12-14
US20120020887A1 (en) 2012-01-26
EP1210068A2 (en) 2002-06-05
US9333174B2 (en) 2016-05-10
CA2382651A1 (en) 2001-03-01
CA2382651C (en) 2009-11-24
AU6929600A (en) 2001-03-19

Similar Documents

Publication Publication Date Title
DK1210068T3 (da) Anvendelse af simple aminosyrer til dannelse af poröse partikler
NO171949C (no) Fremgangsmaate for fremstilling av et farmasoeytisk mikroinnkapslet preparat
ITRM920590A0 (it) Sistema per la realizzazione distrutture in fibra di carbonio, e procedimento per detto, particolarmente idoneo per applicazioni aeronautiche.
ATE285755T1 (de) Grosse poröse partikel erhältlich durch sprühtrocknung und geeignet zur pulmonalen anwendung
DE69921941D1 (de) Verfahren zur Herstellung von pharmazeutischen Wirkstoffpartikeln
EP1832599A3 (en) Albumin fusion proteins
DE69901726D1 (de) Stabile konzentrierte insulin präparationen zur pulmonaren verabreichung
ES2171883T3 (es) Procedimiento para la preparacion de formulaciones de agentes tensioactivos pulmonares en forma de polvos.
DZ2448A1 (fr) Sel du dérivé d'acide de naphthyridine carboxylique.
MY129941A (en) Novel dihydro-isoquinoline derivatives
NO169473C (no) Fremgangsmaate for fremstilling av sfaeriske partikler.
DE60002885D1 (de) Wässrige formulierung zur nasalen verabreichung
NO923424L (no) Ekkogene partikler, fremgangsmaate for fremstilling av slike samt anvendelse derav
NO983437L (no) Faste administreringsformer med umiddelbar frigivelse, samt fremgangsmÕte for fremstilling av slike
DE59005546D1 (de) Dispersionen kugelförmiger anorganischer partikel.
ITBO20010311A0 (it) Impianto per l'essicazione di superfici verniciate, in particolare veicoli e loro parti staccate, e procedimento per il suo controllo
ATE492260T1 (de) Kosmetische zusammensetzung, mit oberflächenhydrophobierter kieselsäure beschichtete metalloxidteilchen, sol von mit oberflächenhydrophobierter kieselsäure beschichtete kieselsäurebeschichteten metalloxiden und verfahren zur herstellung derselben.
IT1216142B (it) Composizioni farmaceutiche agenti sul cuore e sul sistema cardiovascolare e procedimento per la loro preparazione.
IT1232917B (it) Procedimento per la fabbricazione di microsfere tramite reticolazionedi proteine, microsfere cosi' ottenute e loro impieghi
DE59911562D1 (de) Latent vernetzende wässerige dispersionen enthaltend ein polyurethan
DK565486A (da) Carboxylgruppeholdige polyamider, fremgangsmaader til fremstilling heraf samt deres anvendelse til fremstilling af vandige bronzedispersioner
ZA200603236B (en) Methods for the preparation of {2-[8,9-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} phosphonic acid and esters thereof
AU2002316940A1 (en) Process for the preparation of d-pantothenic acid and/or salts thereof
IT1303106B1 (it) Procedimento e sistema per l'attuazione di guasti
ITRM910590A1 (it) Procedimento ellettrochimico per la preparazione dell'acido 4, 4'- dinitrostilben- 2, 2, ' -disolfonico e dei relativi sali